Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | CDKN2A and TP53 mutation in HPV-negative HNSCC

Barbara Burtness • 28 May 2020
ASCO 2020
Head and Neck Cancer Trastuzumab

Barbara Burtness, MD, of Yale Cancer Center, New Haven, CT, discusses the predicitive value of TP53 and CDKN2 mutations in determining tumor mutational burden in HPV negative head and neck squamous cell carcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Barbara Burtness

0:47
Novel KRAS-targeting agents on the horizon
Barbara Burtness • 7 Aug 2022
0:35
Data on KRAS inhibitors in lung cancer at WCLC 2022
Barbara Burtness • 7 Aug 2022
10:08
Evolving role of HER2 targeted therapies in gastroesophageal cancers
Barbara Burtness • 28 May 2020
7:56
KEYNOTE-048: progression post next line for R/M HNSCC
Barbara Burtness • 28 May 2020

Related Videos

1:03
Challenges in implementing liquid biopsies for head and neck cancer
Mouadh Barbirou • 7 Apr 2024
2:43
Molecular profiling of tumor biomarkers in head and neck cancer
Mouadh Barbirou • 7 Apr 2024
1:40
The future of squamous cell carcinoma research at ESMO Asia 2023
Brian Henick • 6 Dec 2023
0:54
The role of immunotherapy in PD-L1 low advanced squamous cell carcinoma
Brian Henick • 6 Dec 2023
The content of VJOncology is intended for healthcare professionals